サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1552661

発作性夜間ヘモグロビン尿症（PNH）の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年

Paroxysmal Nocturnal Hemoglobinuria Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 166 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
発作性夜間ヘモグロビン尿症（PNH）の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年
出版日: 2024年07月17日
発行: Transparency Market Research
ページ情報: 英文 166 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

発作性夜間ヘモグロビン尿症（PNH）市場- 調査範囲

TMRの調査レポート「発作性夜間ヘモグロビン尿症（PNH）の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の発作性夜間ヘモグロビン尿症（PNH）市場の収益と予測を提供しています。また、2024年から2034年までの世界の発作性夜間ヘモグロビン尿症（PNH）市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、発作性夜間ヘモグロビン尿症（PNH）市場を推察しました。

市場スナップショット
2023年の市場規模 38億米ドル
2034年の市場規模 117億米ドル
CAGR 10.8%

当レポートでは、世界の発作性夜間ヘモグロビン尿症（PNH）市場の競合情勢について調査しています。世界の発作性夜間ヘモグロビン尿症（PNH）市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の発作性夜間ヘモグロビン尿症（PNH）市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：治療別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療別、2020-2034年
    • 薬剤
      • エクリズマブ
      • ラブリズマブ
    • サプリメント
    • 輸血
    • 骨髄移植
    • 免疫抑制療法
  • 市場の魅力分析：治療別

第7章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：エンドユーザー別、2020-2034年
    • 病院・クリニック
    • 在宅治療
    • その他（研究機関等）
  • 市場の魅力分析：エンドユーザー別

第8章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020-2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第9章 北米の市場分析と予測

第10章 欧州の市場分析と予測

第11章 アジア太平洋地域の市場分析と予測

第12章 ラテンアメリカの市場分析と予測

第13章 中東・アフリカの市場分析と予測

第14章 競合情勢

  • 市場企業- 競争マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023）
  • 企業プロファイル
    • Alexion Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals
    • Genentec, Inc.
    • Novartis AG
    • The Takeda Pharmaceutical Company Limited
    • Kira Pharmaceuticals
    • F. Hoffman-La Roche AG
    • Akari Therapeutics PLC
    • Omeros Corporation
    • Regeneron Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
  • Table 02: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 03: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 04: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 05: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
  • Table 06: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 07: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 08: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
  • Table 09: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 10: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 11: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
  • Table 12: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 13: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
  • Table 15: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
  • Table 18: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Paroxysmal Nocturnal Hemoglobinuria Market Revenue (US$ Bn), by Treatment, 2023
  • Figure 03: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by Treatment, 2023
  • Figure 04: Global Paroxysmal Nocturnal Hemoglobinuria Market Revenue (US$ Bn), by End-user, 2023
  • Figure 05: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by End-user, 2023
  • Figure 06: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by Region, 2023
  • Figure 07: Global Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 08: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 09: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
  • Figure 10: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 11: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
  • Figure 12: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 13: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Region, 2020-2034
  • Figure 14: North America Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 15: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country, 2020-2034
  • Figure 16: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 17: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 18: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 19: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
  • Figure 20: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
  • Figure 21: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 22: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 23: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 24: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 25: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 26: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
  • Figure 27: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
  • Figure 28: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 29: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 30: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 31: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 32: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
  • Figure 34: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
  • Figure 35: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 36: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 37: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 38: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 39: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
  • Figure 41: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
  • Figure 42: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 43: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 44: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 45: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 46: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 47: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
  • Figure 48: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
目次
Product Code: TMRGL86343

Paroxysmal Nocturnal Hemoglobinuria Market - Scope of Report

TMR's report on the global paroxysmal nocturnal hemoglobinuria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global paroxysmal nocturnal hemoglobinuria market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global paroxysmal nocturnal hemoglobinuria market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the paroxysmal nocturnal hemoglobinuria market.

Market Snapshot
Market Value in 2023US$ 3.8 Bn
Market Value in 2034US$ 11.7 Bn
CAGR10.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global paroxysmal nocturnal hemoglobinuria market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global paroxysmal nocturnal hemoglobinuria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global paroxysmal nocturnal hemoglobinuria market.

The report delves into the competitive landscape of the global paroxysmal nocturnal hemoglobinuria market. Key players operating in the global paroxysmal nocturnal hemoglobinuria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global paroxysmal nocturnal hemoglobinuria market profiled in this report.

Key Questions Answered in Global paroxysmal nocturnal hemoglobinuria Market Report:

  • What is the sales/revenue generated by paroxysmal nocturnal hemoglobinuria across all regions during the forecast period?
  • What are the opportunities in the global paroxysmal nocturnal hemoglobinuria market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Paroxysmal Nocturnal Hemoglobinuria Market - Research Objectives and Research Approach

The comprehensive report on the global paroxysmal nocturnal hemoglobinuria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global paroxysmal nocturnal hemoglobinuria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global paroxysmal nocturnal hemoglobinuria market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Paroxysmal Nocturnal Hemoglobinuria Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Treatment

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment, 2020-2034
    • 6.3.1. Medication
      • 6.3.1.1. Eculizumab
      • 6.3.1.2. Ravulizumab
    • 6.3.2. Supplements
    • 6.3.3. Blood Transfusion
    • 6.3.4. Bone Marrow Transplant
    • 6.3.5. Immunosuppressive Therapy
  • 6.4. Market Attractiveness Analysis, by Treatment

7. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by End-user, 2020-2034
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Homecare Settings
    • 7.3.3. Others (Research Institutes, etc.)
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2020-2034
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Treatment, 2020-2034
    • 9.3.1. Medication
      • 9.3.1.1. Eculizumab
      • 9.3.1.2. Ravulizumab
    • 9.3.2. Supplements
    • 9.3.3. Blood Transfusion
    • 9.3.4. Bone Marrow Transplant
    • 9.3.5. Immunosuppressive Therapy
  • 9.4. Market Value Forecast, by End-user, 2020-2034
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Homecare Settings
    • 9.4.3. Others (Research Institutes, etc.)
  • 9.5. Market Value Forecast, by Country, 2020-2034
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Treatment
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment, 2020-2034
    • 10.3.1. Medication
      • 10.3.1.1. Eculizumab
      • 10.3.1.2. Ravulizumab
    • 10.3.2. Supplements
    • 10.3.3. Blood Transfusion
    • 10.3.4. Bone Marrow Transplant
    • 10.3.5. Immunosuppressive Therapy
  • 10.4. Market Value Forecast, by End-user, 2020-2034
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Homecare Settings
    • 10.4.3. Others (Research Institutes, etc.)
  • 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment, 2020-2034
    • 11.3.1. Medication
      • 11.3.1.1. Eculizumab
      • 11.3.1.2. Ravulizumab
    • 11.3.2. Supplements
    • 11.3.3. Blood Transfusion
    • 11.3.4. Bone Marrow Transplant
    • 11.3.5. Immunosuppressive Therapy
  • 11.4. Market Value Forecast, by End-user, 2020-2034
    • 11.4.1. Hospitals & Clinics
    • 11.4.2. Homecare Settings
    • 11.4.3. Others (Research Institutes, etc.)
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Treatment
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment, 2020-2034
    • 12.3.1. Medication
      • 12.3.1.1. Eculizumab
      • 12.3.1.2. Ravulizumab
    • 12.3.2. Supplements
    • 12.3.3. Blood Transfusion
    • 12.3.4. Bone Marrow Transplant
    • 12.3.5. Immunosuppressive Therapy
  • 12.4. Market Value Forecast, by End-user, 2020-2034
    • 12.4.1. Hospitals & Clinics
    • 12.4.2. Homecare Settings
    • 12.4.3. Others (Research Institutes, etc.)
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Treatment
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Treatment, 2020-2034
    • 13.3.1. Medication
      • 13.3.1.1. Eculizumab
      • 13.3.1.2. Ravulizumab
    • 13.3.2. Supplements
    • 13.3.3. Blood Transfusion
    • 13.3.4. Bone Marrow Transplant
    • 13.3.5. Immunosuppressive Therapy
  • 13.4. Market Value Forecast, by End-user, 2020-2034
    • 13.4.1. Hospitals & Clinics
    • 13.4.2. Homecare Settings
    • 13.4.3. Others (Research Institutes, etc.)
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Treatment
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. Alexion Pharmaceuticals, Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Apellis Pharmaceuticals
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Genentec, Inc.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Novartis AG
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. The Takeda Pharmaceutical Company Limited
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Kira Pharmaceuticals
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. F. Hoffman-La Roche AG
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Akari Therapeutics PLC
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Omeros Corporation
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Regeneron Pharmaceuticals, Inc.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview